Current status of first- and second-line eradication therapy in the metropolitan area: a multicenter study with a large number of patients

Current status of first- and second-line eradication therapy in the metropolitan area: a multicenter study with a large number of patients

Background: The environment surrounding Helicobacter pylori eradication treatment is dramatically changing. Recently, vonoprazan, a first-in-class potassium-competitive acid blocker (P-CAB), was introduced onto the market in 2015. The aging of Japan’s demographic structure is becoming pronounced. In...

Full description

Bibliographic Details
Main Authors: Hideki Mori, Hidekazu Suzuki, Fumio Omata, Tatsuhiro Masaoka, Daisuke Asaoka, Kohei Kawakami, Shigeaki Mizuno, Naoto Kurihara, Akihito Nagahara, Nobuhiro Sakaki, Masayoshi Ito, Yo Kawamura, Masayuki Suzuki, Yuji Shimada, Hitoshi Sasaki, Takeshi Matsuhisa, Akira Torii, Toshihiro Nishizawa, Tetsuya Mine, Toshifumi Ohkusa, Takashi Kawai, Kengo Tokunaga, Shin’ichi Takahashi
Format: Article
Language:English
Published: SAGE Publishing 2019-07-01
Series:Therapeutic Advances in Gastroenterology
Online Access:https://doi.org/10.1177/1756284819858511

Internet

https://doi.org/10.1177/1756284819858511

Similar Items